Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIVATE: Tropifexor + Licogliflozin in NASH with Fibrosis
jRCT2080225078Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of tropifexor and licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Novartis. Primary endpoint: Histologic improvement in fibrosis without worsening of NASH at Week 48. Started Feb 2020; status: completed.
02
Drugs
tropifexorlicogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on jRCT2080225078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225078.